Results 121 to 130 of about 47,532 (242)

Nicotine oxidation by genetic variants of CYP2B6 and in human brain microsomes [PDF]

, 2019
Bloom, Adam Joseph, Kharasch, Evan D, Wang, Pan-Fen   +2 more
core   +2 more sources

The Genetic Blueprint of Obesity: From Pathogenesis to Novel Therapies

Obesity Reviews, Volume 26, Issue 12, December 2025.
ABSTRACT Obesity is a chronic metabolic disease characterized by disturbances in energy homeostasis, leading to excessive fat accumulation. The pathogenesis of the disease is shaped by a complex interplay of genetic, epigenetic, biological, psychological, and environmental factors.
Gašper Tonin, Stjepan Eržen, Zala Mlinarič, Dubravka Jurišić Eržen, Simon Horvat, Tanja Kunej, Jasna Klen   +6 more
wiley   +1 more source

Pityriasis rosea-like drug eruption due to bupropion [PDF]

, 2014
Mualla Polat, Özge Uzun, İsmail Örs, Çetin Boran   +3 more
openalex   +1 more source

Leading Causes of Death in Vietnam [PDF]

, 2017
Vietnam is currently facing a public health crisis. Rates of chronic and preventable diseases are climbing, in addition to mortality rates from these diseases.
Roth, Lindsey
core   +1 more source

Predicting OCT2/MATEs‐Mediated Drug Interactions in Healthy Volunteers and Patients with Chronic Kidney Disease: Insights from Extended Clearance Concept, Endogenous Biomarkers, and In Vitro Inhibition Studies (Perspectives from the International Transporter Consortium)

Clinical Pharmacology &Therapeutics, Volume 118, Issue 5, Page 994-1014, November 2025.
Organic cation transporter (OCT) 2 and multidrug and toxin extrusion (MATE) transporters play significant roles in the renal secretion of organic cations and drug–drug interactions (DDIs). Recent in vitro studies indicate that the Ki values for OCT2 exhibit substrate dependency and increase in potency with pre‐incubation.
Satoshi Asano, Aleksandra Galetin, Yoshiko Tomita, Kathleen M. Giacomini, Xiaoyan Chu, Xinning Yang, Toshimichi Nakamura, Hiroyuki Kusuhara, Yuichi Sugiyama   +8 more
wiley   +1 more source

Vareniclina. Un paso más en la lucha contra el tabaquismo [PDF]

, 2007
Recientemente la Food and Drugs Administration ha aprobado Vareniclina, fármaco para la deshabituación tabáquica que presenta un novedoso mecanismo de acción, agonismo parcial de receptores nicotínicos de acetilcolina a4ß2.Hemos revisado la farmacología,
Donat, Lucas, Ferrando Piqueres, Raúl, Martínez, Beatriz, Milara Payá, Javier, Pérez Prior, Noemí, Soler Company, Enrique   +5 more
core  

Safety and Efficacy of the NMDA‐2b‐Selective Negative Allosteric Modulator BI 1569912: A Phase Ib Randomized Trial in Major Depressive Disorder

Clinical Pharmacology &Therapeutics, Volume 118, Issue 5, Page 1202-1212, November 2025.
Selective N‐methyl‐D‐aspartate receptor subunit 2b negative allosteric modulators (NR2B NAMs) are being explored as potential new treatment options for major depressive disorder (MDD). This Phase Ib, randomized, double‐blind, placebo‐controlled, parallel‐group trial was conducted in adults (N = 59) with moderate‐to‐severe MDD and insufficient response ...
Roger S. McIntyre, Gerard Sanacora, David P. Walling, Elan A. Cohen, Shishuka Malhotra, Holger Rosenbrock, Manuela Schmitz, Andreas Scholz, Sigurd D. Süssmuth, Franco De Crescenzo   +9 more
wiley   +1 more source

Bupropion SR for smoking cessation in smokers with cardiovascular disease: a multicentre, randomised study [PDF]

, 2017
Aim To investigate the safety and efficacy of bupropion sustained release (bupropion SR) in promoting abstinence from smoking in subjects with cardiovascular disease (CVD).
Astbury, C., Farsang, C., Hider, A., Klaene, G., Lewis, K., Manolis, A., Perruchoud, A.P., Silagy, C., Sweet, R., Tonstad, S., van Spiegel, P.I.   +10 more
core  

A geriatrician's approach to managing the complex older adult with obesity

Obesity, Volume 33, Issue S1, Page 41-56, November 2025.
Abstract The prevalence of obesity in older adults is rapidly increasing due to the demographic shift occurring globally. Older adults with obesity face health care challenges due to multimorbidity, functional dependency, and disability. This population often has prior history of struggles through weight‐loss attempts during the middle years of life ...
Shenbagam Dewar
wiley   +1 more source

Naltrexone/bupropion for obesity: An investigational combination pharmacotherapy for weight loss

, 2014
Sonja K. Billes, Puspha Sinnayah, Michael A. Cowley   +2 more
openalex   +2 more sources